Replies to post #8910 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Current Insider Shareholdings and Options

[Updated for grants to officers on 3/7/08 that were part of their
2007 bonuses (#msg-27509339). Other than the options just
granted (which have an exercise price of 0.63), all outstanding
options have exercise prices greater than 1.00.]

 
 	 
 Executive Officers  
 Geoffrey Cox, CEO          351K shares   991K options 
 John Green, CFO            116K shares   414K options 
 Harry Meade, SVP Research  157K shares   383K options 
 Greg Liposky, SVP Oprtns    91K shares   371K options 
 Dan Woloshen, Gen. Counsel 118K shares   287K options 
 Dick Scotland, SVP Regltry  98K shares   267K options 
 -- 
 Six executive officers     931K shares 2,713K options

 
 Non-executive directors  
 Robert Baldridge             5K shares    75K options 
 Kenneth Bauer                 0 shares    38K options 
 Christian Béchon            18K shares    15k options 
 Francis Bullock             11K shares    74K options 
 James Geraghty              88K shares   163K options 
 Michael Landine               0 shares    38K options 
 Pamela McNamara              9K shares    53K options 
 Marvin Miller                8K shares    53K options 
 Alan Tuck                   14K shares    51K options 
 Mary Ann Gray               11K shares    15K options 
 -- 
 Ten non-executive directrs 164K shares   575K options

 
 All officers/directors   1,095K shares 3,288K options

[croumagnon]

Re: "New shares and options for executive officers."

Not too bad and deserved from the point of view of technological progress, although not deserved from the point of view of financing and business deals. Hopefully this will mark the beginning of a pps rise...

I lost track but as I recall these options exercisable at $0.63 are the cheapest options they have. So, I suppose going froward our interest and those of management are aligned in terms of wanting a higher pps...